Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
STE 
STERIS plc (STE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: STE (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
10 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Year Target Price $263.1
Year Target Price $263.1
| 3 | Strong Buy |
| 2 | Buy |
| 5 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 0.32% | Avg. Invested days 54 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 23.49B USD | Price to earnings Ratio 38.76 | 1Y Target Price 263.1 |
Price to earnings Ratio 38.76 | 1Y Target Price 263.1 | ||
Volume (30-day avg) - | Beta 0.94 | 52 Weeks Range 199.99 - 252.20 | Updated Date 06/29/2025 |
52 Weeks Range 199.99 - 252.20 | Updated Date 06/29/2025 | ||
Dividends yield (FY) 0.95% | Basic EPS (TTM) 6.16 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 11.26% | Operating Margin (TTM) 19.95% |
Management Effectiveness
Return on Assets (TTM) 5.82% | Return on Equity (TTM) 9.46% |
Valuation
Trailing PE 38.76 | Forward PE 23.81 | Enterprise Value 25520845075 | Price to Sales(TTM) 4.3 |
Enterprise Value 25520845075 | Price to Sales(TTM) 4.3 | ||
Enterprise Value to Revenue 4.67 | Enterprise Value to EBITDA 18.78 | Shares Outstanding 98371000 | Shares Floating 97991609 |
Shares Outstanding 98371000 | Shares Floating 97991609 | ||
Percent Insiders 0.3 | Percent Institutions 97.82 |
Analyst Ratings
Rating 3.8 | Target Price 263.1 | Buy 2 | Strong Buy 3 |
Buy 2 | Strong Buy 3 | ||
Hold 5 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
STERIS plc
Company Overview
History and Background
STERIS plc was founded in 1985 as Innovative Medical Technologies, Inc. and later renamed STERIS Corporation. Initially focused on infection prevention products, it has grown through acquisitions and organic expansion to become a global leader in sterilization and surgical solutions.
Core Business Areas
- Healthcare: Provides sterilization, cleaning, and infection control products and services to hospitals and other healthcare facilities.
- Applied Sterilization Technologies (AST): Offers contract sterilization and lab services using gamma, electron beam, and ethylene oxide technologies for medical devices and pharmaceuticals.
- Life Sciences: Delivers sterilization, cleaning, and infection control products and services to pharmaceutical, research, and biotechnology companies.
Leadership and Structure
STERIS plc is led by a CEO and an executive management team. The company has a board of directors responsible for overall governance.
Top Products and Market Share
Key Offerings
- Steam Sterilizers: STERIS's steam sterilizers are used in healthcare facilities to sterilize medical instruments and equipment. They hold a significant market share, estimated at ~30-40% in North America. Competitors include Getinge and Cantel Medical (now part of STERIS).
- Surgical Tables: STERIS manufactures surgical tables used in operating rooms. Competitors include Maquet (Getinge) and Mizuho OSI. Market share data is less readily available but estimated to be ~20-30% in North America.
- Ethylene Oxide Sterilization Services: STERIS's AST segment provides EO sterilization services. STERIS has the dominant market share in North America. Key competitor is Medistri SA
Market Dynamics
Industry Overview
The sterilization and infection control market is driven by increasing healthcare spending, stringent regulations, and rising awareness of healthcare-associated infections (HAIs).
Positioning
STERIS plc is a leader in the global sterilization and infection prevention market, known for its comprehensive product portfolio and service offerings. It possesses strong brand recognition and a large installed base.
Total Addressable Market (TAM)
The global sterilization and disinfection market is projected to reach $17.5 billion by 2028. STERIS is positioned to capitalize on this growing market through its diverse product and service offerings. STERIS holds a good TAM market share.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Diversified product portfolio
- Global presence
- Recurring revenue from services
- High barriers to entry in certain segments
Weaknesses
- Exposure to regulatory changes
- Dependence on healthcare spending
- Potential environmental liabilities related to EO sterilization
- Integration risks from acquisitions
Opportunities
- Expansion in emerging markets
- Growth in outsourced sterilization services
- Development of innovative sterilization technologies
- Acquisition of complementary businesses
Threats
- Increased competition
- Pricing pressure from healthcare providers
- Economic downturns impacting healthcare spending
- Stringent regulations on sterilization processes
Competitors and Market Share
Key Competitors
- GETI.F
- SYK
- MMM
Competitive Landscape
STERIS plc competes with other sterilization and infection prevention companies based on product portfolio, service offerings, price, and geographic reach. It has a competitive advantage due to its comprehensive offerings and strong brand.
Major Acquisitions
Cantel Medical
- Year: 2021
- Acquisition Price (USD millions): 3600
- Strategic Rationale: Expanded STERIS's endoscope reprocessing and infection prevention offerings.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is based on the real data
Future Projections: Future Projections are based on real data
Recent Initiatives: Recent initiatives are based on real data
Summary
STERIS plc is a strong player in the sterilization and infection prevention market, driven by its diverse product portfolio and global presence. Its recurring revenue from services and strong brand reputation contribute to its stability. However, it faces regulatory challenges and competition, requiring continuous innovation and strategic acquisitions to maintain its leading position. Recent acquisition of Cantel has shown to be profitable and strategically good to expand the business.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (SEC)
- Investor Presentations
- Industry Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice. Market share data are estimates based on available sources and may not be precise. Financial data is not real and is for structural example only.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About STERIS plc
Exchange NYSE | Headquaters Mentor, OH, United States | ||
IPO Launch date 1992-06-01 | President, CEO & Director Mr. Daniel A. Carestio | ||
Sector Healthcare | Industry Medical Devices | Full time employees 17787 | Website https://www.steris.com |
Full time employees 17787 | Website https://www.steris.com | ||
STERIS plc provides infection prevention products and services worldwide. It operates through three segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in procedure rooms, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument, devices, and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The AST segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of contract sterilization and laboratory facilities, as well as integrated sterilization equipment and control systems to medical device manufacturers and research institutions. The Life Sciences segment designs, manufactures, and sells consumable products, such as pharmaceutical detergents, cleanroom disinfectants and sterilants, pharmaceutical grade and research sterilizers and washers, sterility assurance and maintenance products, vaporized hydrogen peroxide room decontamination systems and sterilizers, and high purity water and pure steam generators. It also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. It serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is headquartered in Mentor, Ohio.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.